"Alemtuzumab" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An anti-CD52 ANTIGEN monoclonal antibody used for the treatment of certain types of CD52-positive lymphomas (e.g., CHRONIC LYMPHOCYTIC LEUKEMIA; CUTANEOUS T-CELL LYMPHOMA; and T-CELL LYMPHOMA). Its mode of actions include ANTIBODY-DEPENDENT CELL CYTOTOXICITY.
Descriptor ID |
D000074323
|
MeSH Number(s) |
D12.776.124.486.485.114.224.060.313 D12.776.124.790.651.114.224.060.375 D12.776.377.715.548.114.224.200.375
|
Concept/Terms |
Campath 1H- Campath 1H
- Monoclonal Antibody Campath-1H
- Antibody Campath-1H, Monoclonal
- Campath-1H, Monoclonal Antibody
- Monoclonal Antibody Campath 1H
- Campath-1H
- Campath1H
Campath 1G- Campath 1G
- Campath-1-G
- Campath 1 G
- Campath1G
- Campath-1G
|
Below are MeSH descriptors whose meaning is more general than "Alemtuzumab".
- Chemicals and Drugs [D]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Blood Proteins [D12.776.124]
- Immunoproteins [D12.776.124.486]
- Immunoglobulins [D12.776.124.486.485]
- Antibodies [D12.776.124.486.485.114]
- Antibodies, Monoclonal [D12.776.124.486.485.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.124.486.485.114.224.060]
- Alemtuzumab [D12.776.124.486.485.114.224.060.313]
- Serum Globulins [D12.776.124.790]
- Immunoglobulins [D12.776.124.790.651]
- Antibodies [D12.776.124.790.651.114]
- Antibodies, Monoclonal [D12.776.124.790.651.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.124.790.651.114.224.060]
- Alemtuzumab [D12.776.124.790.651.114.224.060.375]
- Globulins [D12.776.377]
- Serum Globulins [D12.776.377.715]
- Immunoglobulins [D12.776.377.715.548]
- Antibodies [D12.776.377.715.548.114]
- Antibodies, Monoclonal [D12.776.377.715.548.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.377.715.548.114.224.200]
- Alemtuzumab [D12.776.377.715.548.114.224.200.375]
Below are MeSH descriptors whose meaning is more specific than "Alemtuzumab".
This graph shows the total number of publications written about "Alemtuzumab" by people in this website by year, and whether "Alemtuzumab" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2014 | 0 | 1 | 1 |
2020 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Alemtuzumab" by people in Profiles.
-
Long-term efficacy and safety of alemtuzumab in patients with RRMS: 12-year follow-up of CAMMS223. J Neurol. 2020 Nov; 267(11):3343-3353.
-
Autoimmune hemolytic anemia and thrombocytopenia attributed to an intrauterine contraceptive device. Transfusion. 2015 Mar; 55(3):657-60.
-
Atypical lymphocytic lobular panniculitis. J Cutan Pathol. 2004 Apr; 31(4):300-6.